Ask AI

CCO Official Conference Coverage of IAS 2025: The Latest Updates in HIV *

This program outlines important data and highlights from the 13th International AIDS Society (IAS) Conference on HIV Science.

Share

Program Content

Activities

Themes From IAS 2025
Themes From IAS 2025: Emerging Evidence, Innovations, and Global Challenges
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 11, 2025

HIV Response
Why the HIV Response Must Evolve for People Already Living With HIV
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 01, 2025

18 Capsule Summaries

Activities

ACTG A5391 DO IT
ACTG A5391/DO-IT Trial: Switching to DOR ± TDF vs Continuing INSTI + TAF/FTC in People With Obesity and HIV Infection
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 15, 2025

Ulonivirine and Islatravir
Switch to Ulonivirine + Islatravir in Adults With Virologically Suppressed HIV-1: Phase IIb Trial
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 15, 2025

Real-world LA CAB + RPV With Viremia in OPERA
Switch to LA CAB + RPV in People With HIV and Detectable Viral Load in OPERA Cohort
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 16, 2025

TECAIN
TECAIN: Randomized Trial of Topical Trichloroacetic Acid vs Electrocautery for AIN in People With HIV Infection
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2025

SaDAPT
SaDAPT: Same-Day ART for People With HIV and Presumptive TB in Lesotho and Malawi
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2025

HBV Risk With LA ART
IMPALA Subanalysis: Risk of de novo HBV Infection in Nonimmune People With HIV Using LA CAB + RPV ART
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2025

VOLITION
VOLITION: Interim Analysis From Phase IIIb Trial of Optional Switch to LA CAB + RPV Following ART Initiation on DTG/3TC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2025

ODYSSEY Substudy
ODYSSEY: Predictors of First-line ART Failure in Children With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2025

Trio
Predictors of Significant Weight Gain in People With HIV on ART in the Trio Cohort Over 3-Year Period: Retrospective Analysis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 30, 2025

BREATHER Plus
BREATHER Plus: Short-Cycle vs Continuous ART in Adolescents Living With HIV Receiving DTG + TDF/3TC in Sub-Saharan Africa
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2025

IMPALA
IMPALA: Long-acting Cabotegravir + Rilpivirine in Adults With Poorly Controlled HIV Infection in Sub-Saharan Africa
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 18, 2025

HRF-10071 Phase IIa
HRF-10071: Phase IIa Dose-Ranging, Monotherapy Trial of a Next-generation HIV-1 Maturation Inhibitor in People With HIV Infection
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 18, 2025

MK 8527
Phase IIa Trial of Once-Monthly MK-8527 as Oral PrEP in Adults at Low Risk of HIV-1 Exposure
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 18, 2025

Pregnancy Outcomes With CAB
Antiretroviral Pregnancy Registry Analysis of Pregnancy and Neonatal Outcomes Following Prenatal Cabotegravir Exposure 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 18, 2025

PALM 007 Safety
PALM 007: Safety of Tecovirimat for the Treatment of Mpox in the Democratic Republic of Congo
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 21, 2025

PURPOSE 1 Substudy
PURPOSE 1 Substudy: Efficacy, Safety, and PK of Lenacapavir for PrEP in Pregnant and Lactating People
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 22, 2025

PURPOSE 1 and PURPOSE 2 Results in Adolescents and Young Adults
PURPOSE 1 and PURPOSE 2: Efficacy, Safety, and PK of Twice-Yearly Subcutaneous Lenacapavir for PrEP in Adolescents and Young Adults
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 22, 2025

LEN PrEP Patient Preferences
PURPOSE 2: PrEP Administration Preferences Among Cisgender Men and Gender Diverse Individuals
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 23, 2025

Activities

IAS Conference 2025
HIV Update: CCO Official Conference Coverage of IAS 2025
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 29, 2025

Activities

HIV Update IAS 2025
HIV Update Webinar 2 : CCO Official Conference Coverage of IAS 2025
Video
Congratulations: You achieved a completion on 04/09/2022

Released: July 31, 2025

HIV Update IAS 2025
HIV Update Webinar 1 : CCO Official Conference Coverage of IAS 2025
Video
Congratulations: You achieved a completion on 04/09/2022

Released: August 01, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC  in partnership with the International AIDS Society  

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

IAS

ProCE Banner

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.